Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

289 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany.
Dimitrova D, Naghavi B, Richter R, Nasser S, Chekerov R, Braicu EI, David M, Blohmer J, Inci G, Torsten U, Oskay-Özcelik G, Blau I, Fersis N, Holzgreve A, Keil E, Keller M, Keilholz U, Sehouli J. Dimitrova D, et al. Among authors: blohmer j. BMC Cancer. 2021 Sep 12;21(1):1018. doi: 10.1186/s12885-021-08731-6. BMC Cancer. 2021. PMID: 34511112 Free PMC article.
A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.
Sehouli J, Stengel D, Oskay G, Camara O, Hindenburg HJ, Klare P, Blohmer J, Heinrich G, Elling D, Ledwon P, Lichtenegger W; NOGGO study group. Sehouli J, et al. Among authors: blohmer j. Ann Oncol. 2002 Nov;13(11):1749-55. doi: 10.1093/annonc/mdf294. Ann Oncol. 2002. PMID: 12419747 Free article. Clinical Trial.
Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
Sehouli J, Stengel D, Oskay G, Blohmer J, Kaubitzsch S, Lichtenegger W; Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO). Sehouli J, et al. Among authors: blohmer j. Onkologie. 2004 Feb;27(1):58-64. doi: 10.1159/000075607. Onkologie. 2004. PMID: 15007250 Clinical Trial.
Postoperative therapy modalities for cervical carcinoma.
Kümmel S, Thomas A, Jeschke S, Hauschild M, Sehouli J, Lichtenegger W, Blohmer JU. Kümmel S, et al. Among authors: blohmer ju. Anticancer Res. 2006 Mar-Apr;26(2C):1707-13. Anticancer Res. 2006. PMID: 16617565 Free article. Review.
Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy.
Braicu EI, Fotopoulou C, Chekerov R, Richter R, Blohmer J, Kümmel S, Stamatian F, Yalcinkaya I, Mentze M, Lichtenegger W, Sehouli J. Braicu EI, et al. Among authors: blohmer j. Cytokine. 2013 Mar;61(3):755-8. doi: 10.1016/j.cyto.2013.01.013. Epub 2013 Feb 14. Cytokine. 2013. PMID: 23415672 Clinical Trial.
Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer--results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial.
Braicu EI, Gasimli K, Richter R, Nassir M, Kümmel S, Blohmer JU, Yalcinkaya I, Chekerov R, Ignat I, Ionescu A, Mentze M, Fotopoulou C, Pop C, Lichtenegger W, Sehouli J; Tumor Bank Ovarian Cancer (TOC); German North Eastern Society for Gynecological Oncology (NOGGO). Braicu EI, et al. Among authors: blohmer ju. Anticancer Res. 2014 Jan;34(1):385-91. Anticancer Res. 2014. PMID: 24403492 Clinical Trial.
Shifting cancer care towards Multidisciplinarity: the cancer center certification program of the German cancer society.
Kowalski C, Graeven U, von Kalle C, Lang H, Beckmann MW, Blohmer JU, Burchardt M, Ehrenfeld M, Fichtner J, Grabbe S, Hoffmann H, Iro H, Post S, Scharl A, Schlegel U, Seufferlein T, Stummer W, Ukena D, Ferencz J, Wesselmann S. Kowalski C, et al. Among authors: blohmer ju. BMC Cancer. 2017 Dec 14;17(1):850. doi: 10.1186/s12885-017-3824-1. BMC Cancer. 2017. PMID: 29241445 Free PMC article.
RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial.
Heil J, Sinn P, Richter H, Pfob A, Schaefgen B, Hennigs A, Riedel F, Thomas B, Thill M, Hahn M, Blohmer JU, Kuemmel S, Karsten MM, Reinisch M, Hackmann J, Reimer T, Rauch G, Golatta M. Heil J, et al. Among authors: blohmer ju. BMC Cancer. 2018 Aug 25;18(1):851. doi: 10.1186/s12885-018-4760-4. BMC Cancer. 2018. PMID: 30144818 Free PMC article. Clinical Trial.
Patient-Reported Outcomes and Aesthetic Results after Immediate Breast Reconstruction Using Human Acellular Dermal Matrices: Results of a Multicenter, Prospective, Observational NOGGO-AWOGyn Study.
Blohmer JU, Beier L, Faridi A, Ankel C, Krause-Bergmann B, Paepke S, Mau C, Keller M, Strittmatter HJ, Karsten MM. Blohmer JU, et al. Breast Care (Basel). 2021 Aug;16(4):335-342. doi: 10.1159/000509568. Epub 2020 Sep 16. Breast Care (Basel). 2021. PMID: 34594165 Free PMC article.
Human Acellular Dermal Matrix (Epiflex®) in Immediate Implant-Based Breast Reconstruction after Skin- and Nipple-Sparing Mastectomy and Treatment of Capsular Fibrosis: Results of a Multicenter, Prospective, Observational NOGGO-AWOGyn Study.
Beier L, Faridi A, Neumann C, Paepke S, Mau C, Keller M, Strittmatter HJ, Gerber-Schäfer C, Bauer L, Karsten MM, Kümmel S, Blohmer JU. Beier L, et al. Breast Care (Basel). 2021 Oct;16(5):461-467. doi: 10.1159/000512201. Epub 2020 Dec 11. Breast Care (Basel). 2021. PMID: 34720805 Free PMC article.
289 results